These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Intravesical instillations of capsaicin in urology: from pharmacological principles to therapeutic applications]. de Sèze M; Wiart L; Ferrière JM; de Sèze MP; Joseph PA; Barat M Prog Urol; 1999 Sep; 9(4):615-32. PubMed ID: 10555213 [TBL] [Abstract][Full Text] [Related]
23. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization]. Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182 [TBL] [Abstract][Full Text] [Related]
24. The effectiveness of intravesical oxybutynin, propantheline, and capsaicin in the management of neuropathic bladder following spinal cord injury. George J; Tharion G; Richar J; Macaden AS; Thomas R; Bhattacharji S ScientificWorldJournal; 2007 Oct; 7():1683-90. PubMed ID: 17982563 [TBL] [Abstract][Full Text] [Related]
25. The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics. Sahai A; Khan MS; Arya M; John J; Singh R; Patel HR Expert Opin Pharmacother; 2006 Apr; 7(5):529-38. PubMed ID: 16553568 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352 [TBL] [Abstract][Full Text] [Related]
27. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Haferkamp A; Staehler G; Gerner HJ; Dörsam J Spinal Cord; 2000 Apr; 38(4):250-4. PubMed ID: 10822396 [TBL] [Abstract][Full Text] [Related]
28. Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. Lazzeri M; Beneforti P; Turini D J Urol; 1997 Dec; 158(6):2093-6. PubMed ID: 9366319 [TBL] [Abstract][Full Text] [Related]
29. Pharmacotherapy of the overactive bladder and advances in drug delivery. Cannon TW; Chancellor MB Clin Obstet Gynecol; 2002 Mar; 45(1):205-17. PubMed ID: 11862073 [No Abstract] [Full Text] [Related]
30. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114 [TBL] [Abstract][Full Text] [Related]
31. Intravesical therapy for the treatment of neurogenic bladder in children. Holland AJ; King PA; Chauvel PJ; O'Neill MK; McKnight DL; Barker AP Aust N Z J Surg; 1997 Oct; 67(10):731-3. PubMed ID: 9322726 [TBL] [Abstract][Full Text] [Related]
32. Bladder afferents and their role in the overactive bladder. Fowler CJ Urology; 2002 May; 59(5 Suppl 1):37-42. PubMed ID: 12007521 [TBL] [Abstract][Full Text] [Related]
33. Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia. O'Flynn KJ; Thomas DG Br J Urol; 1993 Nov; 72(5 Pt 1):566-70. PubMed ID: 10071538 [TBL] [Abstract][Full Text] [Related]
34. Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. De Wachter S; Wyndaele JJ J Urol; 2003 May; 169(5):1892-5. PubMed ID: 12686868 [TBL] [Abstract][Full Text] [Related]
35. Mechanisms involved in new therapies for overactive bladder. Cruz F Urology; 2004 Mar; 63(3 Suppl 1):65-73. PubMed ID: 15013655 [TBL] [Abstract][Full Text] [Related]
36. Intravesical oxybutynin chloride: experience with 42 patients. Weese DL; Roskamp DA; Leach GE; Zimmern PE Urology; 1993 Jun; 41(6):527-30. PubMed ID: 8516987 [TBL] [Abstract][Full Text] [Related]
37. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. Madersbacher H; Jilg G Paraplegia; 1991 Feb; 29(2):84-90. PubMed ID: 2023781 [TBL] [Abstract][Full Text] [Related]
38. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Saito M; Watanabe T; Tabuchi F; Otsubo K; Satoh K; Miyagawa I Int J Urol; 2004 Aug; 11(8):592-6. PubMed ID: 15285747 [TBL] [Abstract][Full Text] [Related]
39. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Goldenberg MM Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730 [TBL] [Abstract][Full Text] [Related]